Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -73.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?